Evidence map›Paper›PMID 32499636›Full record

ArticleNature reviews. Immunology2020

COVID-19 vaccines: neutralizing antibodies and the alum advantage.

Peter J Hotez, David B Corry, Ulrich Strych, Maria Elena Bottazzi

Registry-linked trialAbstract read
In one paragraph

Article in Nature reviews. Immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04944095 (Serology Testing), which is not on this map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04944095 unknown statusnot on this mapstarted 2021, after this paper: background citation

Serology Testing (Antibody Levels) With Time Following SARS-CoV-2 (Covid-19) Vaccinations in Residents of Nursing, Extended Care, and Over-55 Communities

TypeobservationalSponsorDr. Sidney J. StohsRan2021 to 2024Enrolled10,000ConditionsCovid-19, Subjects Vaccinated Against Covid-19ArmsChange in SARS-CoV-2 Antibody Levels
3 · Its place in the literature

Who cites it

54 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. COVID-19 vaccine development: milestones, lessons and prospects.Signal transduction and targeted therapy · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Peter J HotezTexas Children's Center for Vaccine Development, Houston, TX, USA. hotez@bcm.edu.
David B CorryDepartments of Medicine (Immunology, Allergy and Rheumatology) and Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA. dcorry@bcm.edu.
Ulrich StrychTexas Children's Center for Vaccine Development, Houston, TX, USA. strych@bcm.edu.ORCID http://orcid.org/0000-0001-9455-7683
Maria Elena BottazziTexas Children's Center for Vaccine Development, Houston, TX, USA. bottazzi@bcm.edu.ORCID http://orcid.org/0000-0002-8429-0476

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adjuvants, ImmunologicAlum CompoundsAnimalsAntibodies, NeutralizingCoronavirus InfectionsCOVID-19 VaccinesHumansMacaca mulattaMiceViral VaccinesAdjuvants, ImmunologicAlum Compoundsaluminum sulfateAntibodies, NeutralizingCOVID-19 VaccinesViral Vaccines

Identifiers

PMID32499636
PMCPMC7271131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.